An assay comparison study was not intended

An assay comparison study was not intended. and the male-to-female ratio was 72% (121 vs. 46 patients; p<0.001). Finally, 18.8% of contacted HCV-RNA positive patients had not been diagnosed previously. Conclusions The HCV seroprevalence was more than four occasions higher compared to current estimates and almost one fifth of contacted HCV-RNA positive patients had not been diagnosed previously. Introduction Chronic infection with the hepatitis C computer virus (HCV) affects an estimated 2C3% of the world's populace and is a leading cause of cirrhosis and hepatocellular carcinoma [1]. With the former standard of care, a combination of pegylated interferon-alfa plus ribavirin, the computer virus could be permanently eradicated in 42C46% of patients with HCV genotype 1 only [2], [3]. However, with the addition of recently approved direct-acting HCV protease inhibitors, treatment success rates have been substantially improved by approximately 20C40% [4], [5], [6], [7]. Patients with advanced liver fibrosis or cirrhosis are less likely to be cured compared to those without relevant fibrosis [8]. Moreover, chronic HCV contamination is usually asymptomatic in the majority of patients and diagnosis is therefore often delayed until more advanced stages of fibrosis are present. Thus, early diagnosis is desirable to optimize overall treatment success. Despite this, national screening programs and surveillance systems are largely heterogeneous across Europe, with reported HCV antibody prevalences ranging from 0.4% to 3.5% by country and from 0.2% to 10.4% by region within countries [9]. Differences in prevalence are largely attributed to variances in transmission routes and differences in public health guidelines [10]. In Germany, the HCV seroprevalence has been estimated to be in the range of 0.4C0.63% in the general populace according to two community-based studies conducted in 1993 to 1996 and 1998, respectively [11], [12], [13]. In clinical practice, HCV antibody testing is routinely performed in risk populations Sodium dichloroacetate (DCA) only (e.g. blood donors, injecting drug users etc.) and in those with unexplained liver enzyme elevations [14]. However, it has been reported that an estimated 15C30% of patients with chronic HCV do not report any risk factors [15] and approximately 20C30% are reported to have persistently normal liver enzymes [16], [17], [18]. Therefore, the number of unreported cases, especially in metropolitan areas with many high-risk groups, may be much higher than previously assumed. The aim of this study was to assess the prevalence of anti-HCV antibodies, HCV-RNA and associated risk factors in patients visiting emergency departments of two urban, tertiary care hospitals. Materials and Methods Study populace The study was conducted in compliance with the declaration of Helsinki and approval was obtained from the Ethics Committee of the Charit C Universit?tsmedizin, Berlin, Germany and the Ethics Committee of the Medical Faculty of the J. W. Goethe University, Frankfurt, Germany. In accordance with the Ethics Committees requirements at the two participating study sites, patients were informed of the study procedure and a notice was displayed on a board. Between Sodium dichloroacetate (DCA) May 2008 and October 2009, extra serum was retained from all consecutive patients of 18 years of age or older who presented to the internal medicine and traumatology emergency departments at the Charit, Campus Virchow-Klinikum in Berlin and who had a blood sample taken as part of their routine diagnostic work up. In addition, extra serum was also retained from consecutive patients of 18 years of age or older who presented to the J. W. Goethe University Hospital emergency department in Frankfurt ECSCR between September 2009 and March 2010. Demographic data, including age, gender, ethnicity and routine laboratory values, including serum aminotransferase levels were collected from hospital admission charts, where available. Upper limit of normal (ULN) values for alanine aminotransferase and aspartate aminotransferase levels were defined as 35 U/mL in females and 50 U/mL in males. HCV antibody screening and sample interpretation HCV antibody screening of blood samples was performed on the same day they were drawn using a fully automated electrochemiluminescence immunoassay (Elecsys? Anti-HCV immunoassay; Roche Diagnostics, Penzberg, Germany) on a cobas e 601 platform. Serum samples with a signal/cut-off (s/co) ratio <0.9 were considered non-reactive, those with a s/co ratio 1.0 were Sodium dichloroacetate (DCA) considered reactive, and samples with results between 0.9 and <1.0 Sodium dichloroacetate (DCA) were interpreted as indeterminate. All samples tested positive or indeterminate by the Elecsys Anti-HCV immunoassay were subsequently stored at ?20 to ?25C and retested with.